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Abstract 
The loss of candidate drugs (CD) due to poor physiological properties or 
incompatibilities with a patients (more commonly referred to as attrition) in the 
pharmaceutical research and development (R&D) process limits throughput, hinders 
productivity and results in large overhead costs.  Much of the attrition in the 
pharmaceutical industry is due to poor physiological properties.  As a result, these 
properties need to be identified as early as possible in the R&D process.  The initial step 
in screening for these properties is identifying (1) all the stable forms of a CD and (2) the 
conditions resulting in nucleation of these solid forms.  Highly complex robotic systems 
have been developed to increase screening efficiency.  These robotic systems enable 
researchers to work on a scale infeasible by hand; however, the number of conditions 
screened is still limited by the volumes required (~100 µl per well), thus the amount of 
material required, and the limited number of wells per device.  Using a microfluidic 
approach allows for earlier screening due to the reduced volumes required.  The 
development of a microfluidic platform to screen for crystallization conditions of CDs is 
presented.  The chip using as little as 50 nl per well on a 96 well chip.  The reduced 
volume and improved control over fluid handling in our microfluidic platforms allow for 
more extensive screening before production has been scaled up.  The microfluidic 
platform studied in this thesis utilizes Free Interface Diffusion, Temperature control and 
Evaporation to control the supersaturation of CDs and therefore induce nucleation.  
Operation and potential has been demonstrated with Acetaminophen screens on-chip.  
Successful chip operation is demonstrated in all three modes using a common Active 
Pharmaceutical Ingredient (API), acetaminophen.  Additionally, the chips have been 
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modified to accommodate analysis by Raman spectroscopy for crystal and polymorph 
identification.   
Incompatibility of PDMS with a wide range of organic solvents has limited the 
analysis on-chip.  To overcome this challenge, more resistant microfluidic platforms are 
needed for example using glass instead of PDMS as the main material for chip 
fabrication.  We are in the process of developing a glass-based microfluidic platform to 
reduce the amount of absorbent material.    
 iv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my Wife 
For Her Love and Support 
  
 v 
 
Acknowledgements 
This work is possible because people supported me, helped me and provided me 
with direction when I needed it throughout my masters.  First, I would like to thank my 
wife, Candi Thorson, for being supportive of me and making my time in Illinois 
enjoyable.   
I am grateful for such a supportive adviser and friend, Paul Kenis, who has 
provided direction and instruction.  He has made working as a graduate student 
productive in a friendly atmosphere.  I appreciate the insight, direction and support 
provided by my adviser, Charles F. Zukoski.  His positive attitude towards research has 
made this work enjoyable.  This research project has been made possible through funding 
from Abbott laboratories.  The continuous support and input by Geoff GZ Zhang and 
Yuchuan Gong from Abbott laboratories has greatly helped me to stay focused and make 
rapid progress.  My coworkers Benjamin Schudel and Sachit Goyal as well as the rest of 
the Kenis group have been instrumental in my research.   
I thank my father for providing support, motivation and advice throughout my 
time in Illinois.  He continually inspires me to work harder through praise.  I thank my 
mother for the love and support she provides.  I thank my grandfather for the support he 
provides.  Most importantly, I want to thank God for providing me the opportunity to 
complete this degree 
 vi 
 
Table of Contents 
Chapter 1: Introduction ....................................................................................................... 1 
1.1 Challenges in the Pharmaceutical Industry in Drug Development ...................... 1 
1.2 Present Challenges in Screening for Crystalline Forms ....................................... 4 
1.3 Microfluidic Approaches for Crystallization Screening ...................................... 6 
1.4 Overall Objectives ................................................................................................ 7 
1.5 Figures .................................................................................................................. 9 
Chapter 2: Design and Fabrication of a Microfluidic Platform for Crystallization 
Screening........................................................................................................................... 12 
2.1 Introduction ............................................................................................................. 12 
2.2 Results and Discussion ........................................................................................... 13 
2.3 Concluding Remarks ............................................................................................... 21 
2.4 Figures .................................................................................................................... 22 
Chapter 3: Application of Crystallization Screens for Identification of Conditions 
Favorable for Crystallization of Active Pharmaceutical Ingredients (API) and Analysis 26 
3.1 Introduction ........................................................................................................ 26 
3.2 Results and Discussion ....................................................................................... 27 
3.3 Challenges Associated with Solvent Absorption ............................................... 30 
3.4 Concluding Remarks .......................................................................................... 32 
3.5 Figures ................................................................................................................ 33 
Chapter 4: Overcoming On-chip Solvent Absorption ...................................................... 36 
4.1 Introduction ........................................................................................................ 36 
4.2 Literature Survey ................................................................................................ 37 
4.3 Coatings to Eliminate Solvent Absorption ......................................................... 39 
4.4 Alternative Materials and Approaches to Eliminate Solvent Absorption .......... 40 
4.5 Concluding Remarks .......................................................................................... 41 
4.6 Figures ................................................................................................................ 43 
Chapter 5: Conclusion....................................................................................................... 45 
5.1 Concluding Remarks .......................................................................................... 45 
5.2 Future Work ....................................................................................................... 46 
Chapter 6: References ....................................................................................................... 47 
 
 
 1 
 
Chapter 1: Introduction 
1.1 Challenges in the Pharmaceutical Industry in Drug Development 
Historically, the top priority regarding drug development has been reducing the 
time to market of candidate drugs (CD) and potential active pharmaceutical ingredients 
(API)[1].  “Time-to-market” is measured as the time from the identification of a CD to 
federal registration and commercial production of an API.  This priority is motivated by 
the long times and associate costs required for CDs to reach production.  In 2003, the 
median time was found to be 7.23 years for a compound to reach market (with a large 
range of 3-21 years) [2].  Increasingly strict standards and regulations have and will 
continue to require more stringent research and development (R&D), thus further 
extending the time for production of APIs.  The long time to market of APIs negatively 
affects the bottom line of pharmaceutical companies due to high R&D costs and the 
deferred time for a return on investment (ROI). 
The pharmaceutical industry also suffers from high attrition regarding CDs [1-3].  
Attrition, defined as the failure of CDs to reach the market, is seen throughout the entire 
drug development process (see Figure 1.1).  Once a lead target is identified in the R&D 
process, it is sent to lead optimization where information is built-up regarding crystalline 
forms, efficacy, and safety of a potential API.  At this point, 93.3% of CDs are eliminated 
based on potential problems, as shown in Figure 1.2 [1, 4].  The CDs that pass lead 
optimization go through preclinical development for feasibility investigations regarding 
scalability, IP, and costs.  Ninety percent of the CDs in preclinical development fail, 
leaving 0.67% of the original CDs for scale-up and clinical studies (phases I, II and III) 
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[1, 4].  Only 0.04% make it past the clinical studies, 0.027% are federally approved and 
only 0.003% of the CDs initially identified based on their pharmaceutical properties have 
a satisfactory ROI [1, 4].  The high rate of attrition amongst CDs makes production of 
APIs very expensive.  The cost to bring a drug to production, a significant portion of 
which is due to attrition, was estimated to be 800 million dollars in 2003 [5].  The high 
rate of attrition amongst CDs and attrition’s effect on the overall cost of bringing APIs to 
market has resulted in drug development priority focusing on early screening of CDs.  
Early screening of CDs assists in identifying physiological properties of CDs. Knowledge 
of these properties lead to the prioritization of CDs based on their likelihood for success, 
therefore, minimizing long R&D processes and attrition.  Early screening also allows 
researchers to prioritize the selection of CDs based on (1) their probability for success 
throughout the R&D process and (2) their potential for a positive return on investment, 
because it eliminates high R&D costs associated with CDs that will otherwise fail at a 
later stage.   
A significant amount of the attrition up through phase III of clinical testing can be 
attributed to poor physiochemical and preformulation properties [6, 7].  These 
problematic properties include solubility, the ionization constant, surface activity, 
stability, solution vehicles and toxicity.  Knowledge of these properties can be used to 
prioritize CD development based on probabilities for success.  Figure 1.3 illustrates the 
various contributing factors for attrition.  Below the major problematic properties are 
highlighted in order to better understand how they bring about attrition and why they are 
important to identify early in the R&D process. 
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Solubility affects dissolution rates, solvent compatibility, toxicity and ultimately 
the performance of APIs [7].  Thus, solubility is a critical factor affecting the length of 
the R&D process as well as a CD’s potential for success or failure.  Solubility data can be 
used to weed out the lowest solubility compounds because of the problems they cause in 
development, e.g. due to low dosages.  Therefore, solubility is one of the key properties 
affecting CD effectiveness. 
The ionization constant determines how pH affects solubility, dissolution rate and 
other properties.   The ionization constant also gives insight regarding how APIs behave 
when co-administered with drugs that change stomach pH [6].  Additionally, ionizable 
compounds can form salts, which increases the number of available solid forms; which, 
in turn, can overcome problematic properties such as hygroscopicity and solid-state 
stability [6].  Identification of ionizable compounds can assist in the identification of CDs 
with high probabilities of success or failure.   
Surface activity is another important property as it can be either harmful or 
helpful, depending on the properties of the CD.  The surface activity typically increases 
solubility in aqueous media, improving compatibility, while it disrupts membranes, 
which can make CDs toxic [6, 8].  Knowledge of this activity is important depending on 
the CD’s function in the body.  Stability of a compound drastically affects its potential for 
reaching the market due to the need for drugs to remain stable on store shelves for 
consumers.  Early knowledge of these properties gives insight regarding the propensity of 
compounds for challenges and attrition in the R&D process.   
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To lower attrition, physiochemical and preformulation properties need to be 
identified as early as possible.  Because the first step in identifying these properties is 
identifying all the solid forms [1], screening needs to be explored as early as possible to 
identify all the available solid forms.  Once all the available solid forms and the 
conditions favorable for crystallization are identified, larger crystals can be nucleated 
using the conditions identified.  These crystals can be tested for their physiochemical and 
preformulation properties in order to improve the selection criteria.  Employing earlier 
detection and establishing a prioritizing system can drastically reduce the cost of bringing 
APIs to market.  Screening needs to (1) begin sooner in the R&D process, (2) encompass 
more extensive sets of conditions to guarantee identification of all solid forms, (3) 
consume less material so testing can commence well before production is scaled up, and 
(4) improve the solid form analysis. 
1.2 Present Challenges in Screening for Crystalline Forms 
Early screening allows for identification of both problematic compounds and 
compounds with the highest probability for success.  While compounds are initially 
selected for their pharmacological and toxicological properties, it is the suboptimal 
physiochemical parameters (e.g. stability, lipophilicity and stability) as well as 
preformulation challenges (e.g. solution vehicles, toxicity) which bring about long R&D 
processes and attrition [1].  Early screening yields insight regarding these parameters and 
understanding regarding CDs’ propensity for failure, thus allowing researchers to focus 
efforts on CDs with higher probabilities for success.  Improved selection reduces 
development times, costs, and complications while providing a faster and safer return on 
investment.   
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The first step in identifying the potentially problematic properties is identification 
of all the available solid forms and the conditions favorable for crystallization.  This level 
of identification requires extensive screens due to the large number of variable 
parameters (e.g. solvents, pH, precipitants, counterions, evaporation rates, temperatures, 
modes of mixing) [9-12].  Additionally, the amount of analyte available for testing is 
typically limited to a few milligrams due to the expenses associated with the production 
of the solid form of CDs in the early stages of drug development.  Because these screens 
require many conditions to be tested with limited material, tests of each parameter must 
consume less material while maintaining consistency and accuracy in testing. 
The ever increasing need for improved early screening has caused pharmaceutical 
screening technology for the identification of solid forms of CDs to grow by leaps-and-
bounds over the last several decades.  The industry transitioned from technicians 
manually screening for crystallization conditions with pipettes to complex, combinatorial 
screening robotic systems for solid form screening.  The combinatorial chemistry 
techniques used today can be traced to the 1960s for solid phase peptide synthesis; 
however, combinatorial screening became widely applied to small pharmaceutical 
compounds in the 1990s [13].   The shift is partially due to the usage of microwell plates 
for crystal screens before the 1980s, which was tedious, time consuming and limited in 
applicability due to the small number of conditions tested [13].  Active ingredients were 
mixed with precipitants, salt solutions, and other solvents by technicians in micro well 
plates who then monitor these plates for the occurrence of crystallization.  This technique 
required large sample volumes (microliters per condition tested), had limited capability 
regarding the brute number of conditions that could be tested, and was quite time 
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consuming.  In the 1980s, robotic systems were developed to take the place of technicians 
[13].  An example robotic screening tool can be seen in Figure 1.4 [14].  These robotic 
systems enable researchers to work on a scale infeasible by hand.  Robotic systems 
accurately pipette API solutions with various compounds in micro wells.  While this 
technology is faster,  more accurate, and less wasteful of sample than manual methods, 
the number of conditions screened is still limited by the volumes required (~100 µl per 
well) and the number of wells per device [14].  The development of very large-scale 
integrated (VLSI) microfluidic techniques for screening has opened the door to more 
efficient pharmaceutical screening with promise to improve the early stage screening of 
APIs for favorable solid forms [15]. 
1.3 Microfluidic Approaches for Crystallization Screening 
The development of a microfluidic platform for crystallization screening has the 
potential to identify a much larger number of available solid forms of CDs early in the 
R&D process which, in turn, can provide much needed data regarding the solubility, 
bioavailability, dissolution rate, impurities and stability of APIs.  Advantages of a 
microfluidic approach include reduced sample volume per test condition, increased 
number of conditions tested, reduced peripheral equipment, lower cost and improved 
fluid control.   
Microfluidics as a field has grown by leaps and bounds since the 1990s to the 
point that large microfluidic chips with precise control and on-chip metering can be 
integrated into stand-alone unit operations [4-6].  Additionally, microfluidics for the 
application of crystallization screening have seen tremendous growth as is seen by the 
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development of microfluidic platforms that screen for crystallization conditions, 
solubility, and nucleation kinetics of crystalline materials [7-11].  Highly integrated 
microfluidic platforms have been developed to screen for crystallization conditions of 
proteins using FID [9].  However, these platforms do not incorporate all of the modes of 
crystallization seen in macroscale crystallization, including evaporation and temperature 
control.  Additionally, the valves used in these microfluidic devices require positive 
pressure to maintain isolation between adjacent chambers and lines [6, 9, 12-15].  The 
use of valves which fail closed would allow chips to be disconnected from peripheral 
connections, e.g., for X-ray or raman analysis.  Other groups have developed microfluidic 
devices to screen for crystallization conditions using oil submersion methods utilizing 
two phase flow on PDMS chips [7, 8, 16-18].  These devices are well adapted to carry out 
one method for crystallization (FID, Temperature or Evaporation) and employ simple 
fabrication techniques.  Microfluidics has demonstrated itself as an excellent platform to 
screen for crystalline conditions due to its inherent advantages of small volumes, high 
level of fluid control, and ability for scaling-out. 
1.4 Overall Objectives 
The overall objective of our research is to develop microfluidic chips to improve 
screening efficiency for solid forms of CDs.  This will enable earlier screening in the 
drug development process thereby increasing the information available to researchers 
regarding crystalline properties.  This information will allow researchers to focus on the 
materials with the highest probability of short R&D timetables and profitable returns on 
their investments.   
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This thesis presents the development of a microfluidic platform for the screening 
of a wide range of solid forms of CDs and for the conditions favorable for crystallization.  
The PDMS chip mixes a CD in a combinatorial fashion with precipitating agents, 
antisolvents, or counterions.  Nucleation is induced through free interface diffusion, 
temperature control, or evaporation.  Chapter 2 discusses the microfluidic platform’s 
design, fabrication and operation.  Chapter 3 discusses the application of the microfluidic 
platform for the screening of crystallization conditions of acetaminophen, a common 
API.   Chapter 4 discusses challenges regarding solvent absorption of non-aqueous 
solvents into PDMS.  A variety of materials from literature and materials used in our lab 
are discussed as potential alternatives for a PDMS platform.  Current progress towards 
the development of a glass based microfluidic device is discussed in detail.  Finally, 
Chapter 5 summarizes the key conclusions from this work and describes the future 
directions of this project. 
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1.5 Figures 
 
Figure 1.1 The R&D process from lead discovery (left) through CD development to 
launch of an API [1]. 
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Figure 1.2 Attrition throughout the R&D process.  The “likelihood of project survival at 
discrete stages along the R&D time line” [1]. 
 
Figure 1.3 Contributing factors to attrition in the pharmaceutical industry.  Of note are 
the bioavailability, formulation, efficacy, clinical safety and toxicology which can be 
reduced with improved screening capabilities [16]. 
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Figure 1.4 Example of a SYMYX system used for crystallization screening.  This highly 
complex robotic system used robotic pipettes to meter fluids into wells and perform 
crystallization studies [17]. 
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Chapter 2: Design and Fabrication of a Microfluidic Platform 
for Crystallization Screening 
2.1 Introduction 
The cost of bringing an Active Pharmaceutical Ingredient (API), better known as 
a pharmaceutical drug, to market was estimated to be 800 million dollars in 2003 [5].  
Much of the expense associated with bringing APIs to market comes from the extensive 
R&D of candidate drugs (CD) that fail in testing [13].  As a result, it is critical to speed 
up the testing process and provide the information needed to remove CDs from 
development early on to reduce R&D on CDs that fail testing and ultimately lower the 
cost of bringing a compound to market.  In order to provide information regarding 
bioavailability, stability, etc. of CDs earlier in the R&D process, more efficient screening 
technology needs to be developed for the identification of all available solid forms of 
CDs.  
The development of a microfluidic platform has the potential for providing much 
needed data regarding solubility, bioavailability, dissolution rate, impurities and stability 
of CDs early in the R&D process.  This information will provide researchers insight 
regarding whether CDs will ever reach the market, thus allowing researchers to focus on 
compounds more likely to reach the market.  We propose to develop a microfluidic 
platform to screen for all the available solid forms of CDs while using less material, 
screening for more conditions and providing better control than state-of-the-art robotic 
macroscale approaches. Additionally, our microfluidic plan will utilize the microfluidic 
technology already demonstrated to screen for proteins and small molecules [18].  This 
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platform employs evaporation, temperature control and free interface diffusion as the 
method to drive supersaturation up and therefore nucleation.  These methods have the 
highest probability of identifying crystallization conditions, thus maximizing the number 
of solid forms identified.  Building on the designs of other microfluidic combinatorial 
mixers, we developed a device that mixes API solutions with precipitant and salt 
solutions in a combinatorial fashion [19].  The combinatorial mixing maximizes the 
number of unique conditions screened.  We utilize Actuate to Open (ATO) valves, which 
close when disconnected from peripheral connections, thus allowing the device to be 
transported between analytical tools [19, 20].  Using acetaminophen, chip operation has 
been demonstrated using evaporation, temperature control and free interface diffusion.  
For analysis, we use Raman spectroscopy and birefringence on-chip.  The inclusion of 
Raman is critical as it allows for polymorph detection [21].  The device has a total of 96 
wells and uses 50 nl per well.  The platform has the scalability, volume, and fluid control 
advantages associated with microfluidics while maintaining the versatility of macro-scale 
tools. 
2.2 Results and Discussion 
First, the design of the microfluidic platform is detailed.  Then, the fabrication is 
explained and finally, device operation is demonstrated with dyed solutions.   
2.2.1 Design of Microfluidic Crystallization Screening Platform 
This microfluidic device was designed to mix API solutions with many 
precipitating solutions, salt solutions, and solvents in a combinatorial fashion to 
maximize the number of conditions analyzed for solid formation.  The device uses a 
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repeating structure that enables the metering of fluids in a combinatorial fashion, simple 
diffusion mixing, well isolation, minimal sample waste, simple controls and a robust 
design.  Figure 2.1 lays out the repeated structure critical to the device operation, which 
consists of three components: (1) the chamber for the pharmaceutical component, (2) the 
chamber for the precipitating agent, salt solution or other solvent and (3) the chamber for 
evaporation.  These chambers are filled independently to create unique combinations of 
CD solutions with their respecting precipitating agents, salt solutions or solvents.  Once 
filled, mixing is employed within these chambers.  When using the evaporation mode, the 
fluid is transferred to the evaporation chamber which allows the solvent to evaporate at a 
rate set by the evaporation lines (Figure 2.1).   
The power of using a microfluidic approach comes with the ability to scale out 
and thus screen a large array of conditions, with the microscale advantage of reducing the 
sample volume per condition screened.  Figure 2.2 demonstrates how the repeated 
structure shown earlier can be replicated on a 7x12 chip to create a large number of 
integrated wells.   
To accomplish the filling, mixing, transfer of fluids and evaporation rates 
discussed earlier, several layers are incorporated into the design.  The fluid layer houses 
all the fluids and, therefore contains the chamber for the API solution, the chamber for 
the precipitant solutions, salt solutions, or other solvents as well as the evaporation 
chamber and fluid lines, as shown in Figure 2.3.  Fluid transfer and mixing is controlled 
in this layer.  PDMS (polydimethyl siloxane) is used for this layer due to its propensity 
for bonding to other surfaces and its elastomeric properties. 
 15 
 
A control layer with valves embedded is used to control the movement and 
mixing of fluids in the fluid layer.  The control layer sits on top of the fluid layer, as 
shown in Figure 2.3, and controls the fluid movement through valve actuation.  The 
control layer is made out of PDMS to improve bonding with the fluid layer.   
Traditionally, positive pressure valves are used for on-chip metering of fluids [18, 
22].  The typical structure of a positive pressure valve is shown in Figure 2.4.  When 
positive pressure is applied to the valve control line, the valve compartment is pushed up 
into the fluid layer, closing the channel or well.  While this technique works for closing 
channels, these valves are prone to leaks along the edges and the valves require external 
pressure to hold the valves closed.  These challenges force all testing to be done in one 
location and limit the time of experiment.  In order to overcome these challenges, actuate-
to-open (ATO) valves have been used.  The structure is shown in Figure 2.5.  ATO 
valves are closed in rest, thus keeping fluidic compartments isolated, and minimize leaks, 
thus allowing us to disconnect the device from peripherals for testing.  However, the 
incorporation of ATO valves into a high density chip is challenging due to pressure losses 
on-chip.  Large chips require complex valve structures; which result in long valve lines.  
Longer valve lines are problematic because long valve lines lose pressure over long 
distances due to the permeability of gas in PDMS.  These pressure drop losses required 
changes in the valve design.  The pressure loss was found to decrease when the ratio of 
the channel cross sectional area to the channel surface area increased.  The control lines 
were made thicker which increased the cross sectional area relative to the surface area 
and thus allowed for valve actuation on longer valve lines. 
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Additionally, several layers which are not typically used in microfluidics have 
been incorporated to enhance operation.  An impermeable layer, a standard self adhesive 
laminating sheet (polyvinyl chloride), is used above the control layer, as shown in Figure 
2.3, to eliminate solvent evaporation out of the PDMS into the ambient air.  Additionally, 
a gold coating, shown in Figure 2.3, has been applied to the glass slide backing of the 
device.  The gold coating eliminates noise from the glass backing when using Raman 
microscopy on-chip. 
2.2.2 Fabrication of Microfluidic Platform 
The microfluidic device consists of several layers.  Each layer is made of a 
different material, thus requiring a complex fabrication procedure.  The fluid and control 
layers are patterned using standard soft lithographic procedures [23, 24].  A silicon wafer 
is patterned with SU8-50 via spin coating at 2000 RPM to make a 50 µm thick pattern.  
The coated wafer is prebaked, patterned in a UV exposure tool using a computer-
generated negative mask, postbaked and developed.  The fluid and control layers are 
patterned by coating the silicon wafer with PDMS (Slygard 184).  The control layer is 5:1 
(slygard 184: crosslinking agent) and the fluid layer is 15:1.  PDMS is spun onto the 
silicon wafers at 1250 RPM to make each layer 75 µm thick.  After each layer is partially 
baked for 20 minutes at 70°C, the control layer is transferred from its corresponding 
silicon master to the fluid layer where it is aligned and fully baked.  Because the control 
layer is only 75 µm thick and the features are 50 µm thick, the device cannot be removed 
from its silicon master using standard procedures, as the device will tear.  As a result, a 
stamp, shown in Figure 2.5, is used to transfer the control layer onto the fluid layer.  A 
PMDS stamp in the form of a window (5:1) is bonded to the control layer beyond the 
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features of the device to make the device rigid enough to be removed.  However, the 
control layer still cannot be removed from the silicon wafer without tearing the device.  
As a result, hexane, a highly absorbent solvent in PDMS, is used to de-seal the device 
from the silicon wafer.  Hexane swells PDMS enough that the control layer can be easily 
removed as shown in Figure 2.6.  After the control layer is removed, it is washed with 
water to restore the device to normal size, dried with nitrogen gas and aligned to the fluid 
layer where it is permanently sealed with an additional bake at 70°C for 30 minutes. 
Once holes are punched in the PDMS device for inlets, an impermeable layer is 
applied to the top of the control layer via a self adhesive to eliminate absorption.  The 
fluid and control lines sit on top of evaporation lines which are made out of NOA 71 
(Norland Optical), a Thiol-Ene material.  The fluid lines are fabricated out of a PDMS 
master.  The same technique discussed earlier for the fabrication of silicon masters for 
PDMS molding is used to create positive silicon masters.  The silicon master is used in 
turn to fabricate PDMS masters.  The PDMS (5:1) is poured on the ~2 mm silicon wafer 
and baked for 45 minutes at 70°C.  The PMDS mold is then used to make the evaporation 
channels.  NOA 71 is spun onto the PDMS mold at 500 RPM and crosslinked using UV 
exposure for 10 minutes at 10 mW/cm2. Once crosslinked, the combined fluid layer, 
control layer, and impermeable layer is adhered to the Thiol-Ene layer with pressure.  
The whole device is pressure-bonded to a glass slide with a Cr/ Au coating.  The glass 
slide is coated with the Cr / Au combination in a sputter coater (AJA International).  The 
chrome is used to improve the adhesion of gold, and gold is used to enhance Raman 
spectroscopy on-chip. 
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2.2.3 Operation of Microfluidic Platform for Filling, Mixing, Free Interface 
Diffusion, Temperature Control and Evaporation 
For proper device operation, various solutions containing a CD must be 
introduced into the chip to fill different compartments.  Once on-chip, the solution must 
be mixed, transferred, evaporated, etc.  This chip gives an operator the control and the 
screening potential necessary to analyze many conditions with one sample.  Below, chip 
operation to maximize the screening potential of CDs is discussed. 
CDs for testing are produced off-chip.  The compounds are dissolved in solvents 
of interest and loaded onto the chip with Teflon tubing or by pipetting fluid directly over 
the access holes on-chip.   Once loaded, the fluid is introduced into the chip through the 
actuation of the ATO valves and the application of vacuum pull fluid in.  By selectively 
opening a series of valves, fluid can be directed and moved through a chip to fill the 
appropriate chambers.  The valves have been designed to fill the chip in a combinatorial 
fashion.  Figure 2.2 highlights the combinatorial sample formulation capabilities using 
food dye for demonstration purposes.  On-chip, we create a large array of conditions with 
unique API: precipitant mixtures to maximize the number of conditions screened in a 
single test. 
More specifically, the device is filled in a series of steps illustrated in Figure 2.6.  
The API and precipitating agent are filled independently via valve actuation in a 
combinatorial fashion.  Once filled, one of the following methods is employed depending 
on the mode of crystallization desired: 
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Free Interface Diffusion – The valves separating the chamber housing the 
precipitating agent and the chamber housing the pharmaceutical component is opened as 
shown in Figure 2.7, allowing for slow diffusional mixing between the two chambers.  
The time for the API solution to fully mix with the precipitating solution can be estimated 
with the following equation: 
 𝑡𝑡 = 𝑥𝑥22𝐷𝐷                                                                                                                (2.1) 
where t is the time for mixing, x is the distance for mixing and D is the diffusivity of the 
compound [25, 26].  Using the diffusivity of acetaminophen, 4.25 × 10−6 cm 2s [26], and 
estimating the distance for mixing  to be 1mm, we calculate the time required for mixing 
to between 19 and 20 minutes.  Dyed solutions with diffusivities similar to 
acetaminophen have been observed to mix in roughly 20 minutes, which agrees with the 
above calculation. 
In some cases, it may be desirable to speed up mixing to better simulate 
microbatch macro-scale techniques.  To accomplish this, a valve has been added which 
can push the fluid from the two wells back and forth.  Through visual observation with 
food dyes, the mixing time has been determined to be less than 3 minutes. 
Temperature – After mixing using the technique described above, the temperature 
is controlled externally via a peltier heater/cooler (20/20 Technologies) to induce 
crystallization.  The temperature can be controlled from 0°C to 60°C.  The peltier device 
can be placed on the microscope stage with the chip placed within the temperature 
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control device for in situ and live analysis.  The wide temperature range increases the 
likelihood for nucleation. 
Evaporation – After mixing using one of the techniques of microbatch or FID, the 
fluid is transferred into the evaporation chamber by opening a valve connecting the 
evaporation chamber to the chamber for the pharmaceutical component.  The evaporation 
mode is shown in Figure 2.7.  Once in the evaporation chamber, the evaporation rate is 
set by the dimensions of the evaporation line.  The evaporation rate depends on the cross-
sectional (𝐴𝐴𝑐𝑐) area of the evaporation channel and the length (𝐿𝐿) of the evaporation 
channel according to the following equation [25]: 
𝐽𝐽 = 𝐴𝐴𝑐𝑐
𝐿𝐿
∙ 𝐷𝐷 �
𝑃𝑃∗
𝑃𝑃𝑇𝑇
� 𝜌𝜌 ∙ 𝑀𝑀𝑀𝑀           (2.2) 
where Ac is the cross sectional area, L is the length, D is the diffusivity, P∗ is the vapor 
pressure, PT is the total pressure, ρ is the density and MW is the molecular weight. 
Using this design equation, the chip has been designed such that four different 
sets of wells evaporate between 10 and 100 hours.   Experimentally, we have found that 
the wells evaporate in 7, 24, 36, and 41 hours when using aqueous media.  The difference 
can be attributed to the absorption of solvent into the PDMS.  Although the solvent loss is 
minimized through the reduction of the PDMS thickness and the incorporation of an 
impermeable layer, some solvent still is absorbed into the surrounding PDMS.  
Nonetheless, the absorption rates can be accounted for via modifications of the 
evaporation channel dimensions to give the desired evaporation rates. 
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2.3 Concluding Remarks 
This chapter described the design and fabrication of a microfluidic device for 
crystallization of CDs.  The microfluidic chip described integrates the technology and 
robustness seen on the macro-scale in a microfluidic device without sacrificing the 
variety of testing methods and versatility seen on the macro-scale.  Using a microfluidic 
approach allows for the reduction of the volume required per condition screened (~50 nl), 
provides large arrays, improves fluid control in mixing, minimizes peripheral equipment, 
and provides portability.  Additionally, this platform has several advantages over other 
microfluidic crystallization screening approaches reported in literature.  We utilize a fail 
closed valve, thus eliminating leaks between adjacent compartments and providing 
portability by allowing the device to be disconnected from peripheral equipment.  We 
integrate several modes of driving supersaturation to induce nucleation and growth.  This 
device has the potential to generate many conditions favorable for crystallization and 
identify many more solid forms of CDs in the initial stages of drug development.  Thus, 
the platform has the potential to reduce time and cost related to bringing new drugs to the 
market. 
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2.4 Figures 
 
 
 
Figure 2.1 The repeated structure of the microfluidic device.  Each set of wells contains 
chambers for (1) the pharmaceutical component, (2) the precipitating agent, and for (3) 
evaporation.  The precipitant and pharmaceutical chambers are filled independently.  
These chambers are mixed following filling and transferred to the evaporation chamber. 
 
 
 
Figure 2.2 Demonstration of the screening on our 7x12 microfluidic chip.  Red, yellow 
and orange lines are filled horizontally and mixed with green and blue vertical lines. 
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Figure 2.3 Schematic overview of the layered assembly of the microfluidic 
crystallization chip.  The impermeable layer eliminates absorption and evaporation 
beyond the control layer.  The control layer is made of PDMS because the fabrication is 
well understood and it bonds well to the fluid layer.  The fluid layer is made of PDMS 
because its elastomeric properties allow for valve actuation.  The evaporation channels 
are made of a Thiol-Ene material for its low absorption.    This device sits on a gold 
coated (to eliminate raman signal from glass) glass slide (to provide a rigid backing). 
 
Figure 2.4  Actuate-to-Close valves made with soft-lithographic techniques [27].  Shown 
schematically is the actuation of the valve with pneumatic pressure.  Figure from Josh 
Tice [28]. 
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Figure 2.5 Actuate-to-Open (ATO valves made with soft-lithographic techniques.  
Shown schematically is the actuation of the valve. 
 
 
 
Figure 2.6 Use of highly absorbent solvent to remove control layer from silicon wafer.  
The (A) 75µm control layer is de-sealed with the (B&C) addition of hexane.  This allows 
the control layer to be (D) removed without any tears.  Once removed, the PDMS film 
can be (E) cleaned with water to remove hexane, (F) bonded and aligned to the fluid 
layer. 
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Figure 2.7 Filling procedure for a set of wells.  Initially, a compartment is filled 
horizontally with the CD by selectively actuating valves which enable the fluid to transfer 
horizontally.  Then the precipitant chamber is flushed by actuating the valves allowing 
fluid to flow horizontally and pulling the fluid out with a vacuum.  Once flushed, the 
precipitating chamber is filled with a precipitant. 
 
  
 
Figure 2.8 Operation of microfluidic platform for (A) FID, (B) temperature control and 
(C) evaporation. 
 
  
Flush
Fill 
Counterion
Fill Pharm. 
Component
1 mm
Transfer Finish Transfer
Mix
B. Temperature
C. Evaporation
OR
Mix
Mix
Optional – Convection added 
through additional valve
A. FID
Temperature used to 
induce crystallization
Wells evaporated from 
evaporation chambers
Enhance Mixing
 26 
 
Chapter 3: Application of Crystallization Screens for 
Identification of Conditions Favorable for Crystallization of 
Active Pharmaceutical Ingredients (API)  
and Analysis 
3.1 Introduction 
The previous chapters demonstrated the operation and development of a 
microfluidic chip with the proposed application of screening for crystalline conditions of 
candidate drugs (CDs).  The chip can screens many conditions using minimal material, 
and employs exceptional fluid control with regard to combinatorial filling, precise 
metering, controlled diffusional mixing, and controlled evaporation.  Chip operation for 
the following three modes of nucleation will been demonstrated: (1) FID mixing with the 
ability to add convective mixing to simulate microbatch, (2) temperature control with the 
ability to control the temperature on-chip between 0°C and 60°C, and (3) evaporation 
with the ability to control the time for evaporation between 7 and 50 hours. 
The ability of this chip to screen for conditions favorable for the crystal 
nucleation and growth of an active pharmaceutical ingredient (API) is demonstrated 
using the known API, Acetaminophen, as an example.  Acetaminophen (more commonly 
known as Tylenol) was chosen due to its wide use as an over the counter drug.  
Acetaminophen is used as a target compound and is tested on-chip using FID, 
temperature control and evaporation to identify conditions favorable for crystal 
nucleation and growth.   
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Additionally, two methods have been developed for on-chip analysis of CDs.  
Birefringence is used to determine if crystalline material have formed and identify the 
solid form of the crystalline material.  However, birefringence doesn’t provide insight 
regarding the exact nature of the crystal formed.   It cannot distinguish between different 
polymorphs.  Researchers have shown that Raman spectroscopy can identify different 
polymorphs of compounds [29].  Due to the improved identification possible with the 
incorporation of Raman spectroscopy, we have adapted our microfluidic chips to enable 
analysis of crystals on-chip using Raman spectroscopy. 
3.2 Results and Discussion 
Acetaminophen is supersaturated and nucleated using FID in an antisolvent setup, 
temperature control and evaporation.  All experiments can be carried out on an upright 
microscope.  Chips are filled manually with a vacuum pump.  Once filled and mixed, the 
microscope stage is programmed to monitor activity in the cells over specified intervals 
at specified coordinates.  Additionally, the temperature profile is programmed.  Once set 
up, the stage is allowed to run as programmed.  Finally, the data is analyzed after the 
experiment has completed. 
3.2.1 On-chip Crystal Screening of Potential APIs 
The first on-chip experiment discussed is crystallization of acetaminophen with 
FID.  An acetaminophen (Sigma Aldrich) in methanol stock solution at the temperature 
solubility of 50°C was used in the subsequent experiments to identify nucleation 
conditions.  The stock solution was screened against several antisolvents including water, 
methanol, ethanol, isopropanol, and butanol.  Using pipettes, solutions were loaded onto 
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the microfluidic device at the inlet ports and pulled into the device via valve actuation 
with negative pressure.  After filling and mixing, each well was monitored for 
crystallization conditions.  We observed that 10 of the 15 tested conditions resulted in 
nucleation. 
For comparative purposes, identical concentrations were mixed using an oil 
submersion method (microbatch).  Using the oil submersion method on the macro-scale, 
we observed nucleation in 7 of the 15 conditions tested.  The increased number of “hits” 
seen in the microfluidic experiment compared to the macro-scale microbatch experiment 
can be attributed to the increased levels of supersaturation seen in a FID approach.  The 
higher levels are supersaturation and observed as the compounds slowly diffuse into the 
corresponding precipitant solutions. 
The next on-chip crystallization experiment involved nucleation of 
Acetaminophen with temperature control.  Acetaminophen solutions with concentrations 
ranging from 0.0015 g/ml to 0.0045 g/ml in water were created on-chip through our 
combinatorial mixing approach.  Once loaded and mixed, the temperature of the device 
was lowered from 50°C to -5°C to induce crystal nucleation and growth.  We observed 
nucleation in wells with acetaminophen concentrations greater than 0.002 g/g.  This result 
demonstrates the ability to generate crystalline material using a temperature controlled 
microfluidic approach.  Beyond identifying crystalline forms of Acetaminophen, the 
solubility of Acetaminophen was identified.  The device temperature was raised, which 
caused the crystals in the wells to dissolve.  The temperature at which the wells dissolved 
correlated to the solubility temperature of the crystals.  
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The third on-chip crystallization experiment used evaporation to induce 
nucleation.  The evaporation rates are controlled through a combination of absorption and 
evaporation.  The absorption rate is governed by the ratio of PDMS to solvent and the 
dimensions and design of the channels.  The evaporation rates are governed by the ratio 
of the cross sectional area to length of the channel as discussed in chapter 2.  In Figure 
3.2, we demonstrate the nucleation of crystals in wells via evaporation for demonstration 
purposes.  The device has been designed to control evaporation rates such that the solvent 
within the wells evaporate in 10 to 50 hours.  These slow nucleation rates improve the 
probability of crystalline growth rather than amorphous material.  Acetaminophen at the 
temperature solubility of 30°C was introduced into the microfluidic chip through inlet 
ports and transferred to the evaporation chambers where the solvent in the wells was 
evaporated.  The API within the wells was consistently nucleated. 
3.2.2 Characterization of Crystals Grown On-chip 
The identification of the solid forms of CDs on-chip both in terms of solid 
formation (crystalline or amorphous) and polymorphism is critical to proper analysis.  
Birefringence can be used for solid form identification.  Two polarized filters are fitted to 
the light source and the detection microscope so that crystalline material can be 
visualized with the microscope.  Figure 3.3 demonstrates the incorporation of 
birefringence in the FID experiment discussed earlier, revealing easily identifiable 
crystalline forms.   
While microscope analysis using birefringence is simple to implement and 
provides identification of solid formations of the crystals, the method does not typically 
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provide insight regarding polymorphism.  Thus, we chose to use Raman spectroscopy for 
polymorph, crystal structure and compound identification.  Enabling Raman spectroscopy 
of crystals on-chip required several modifications to the chip design.  Early designs 
which used a chip with 2 mm of PDMS and a 1mm glass backing resulted in poor 
spectroscopy (we tested Acetaminophen, Adipic Acid and Lysozyme).  Reducing the 
PDMS thickness to <150 µm and applying a gold coating to the glass slide allowed us to 
eliminate noise from both PDMS and glass.  Applying a gold coating to the glass slide 
reflected the Raman laser back though the device, rather than through the glass slide, thus 
completely eliminating the noise from the glass.  Both of these changes allowed us to 
obtain quality Raman spectra of APIs on chip.  Figure 3.4 demonstrates quality Raman 
spectra obtained on-chip for acetaminophen.  Of note is that the peaks observed from 
acetaminophen off-chip correlate strongly with the peaks of acetaminophen on-chip. 
3.3 Challenges Associated with Solvent Absorption 
The success of this chip for crystallization of APIs in aqueous solvents has been 
demonstrated with relatively long time scales (order of days) and organic solvents with 
short time scales (order of hours).  However, PDMS tends to absorb organic solvents, 
limiting us to short term experiments when using organic solvents.  This absorption 
presents a challenge due to the higher solubilities of most APIs in organic solvents.  We 
would like to carry out longer experiments with organic solvents (e.g. methanol, ethanol, 
isopropanol) to identify more solid forms and conditions favorable for crystallization.  
The original chip was designed with aqueous media in mind; thus, a reduction of the 
PDMS layer to 150 µm was sufficient to minimize aqueous absorption (see equations 
below).  In order to quantify the fraction of solvent available to absorb into the 
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surrounding PMDS, the solvent on-chip, the amount of PDMS in contact with the 
solvent, and the absorbance of the PDMS for the solvent must be known.   
The solvent on chip can be calculated based on the number of wells on-chip 
(𝑁𝑁𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤 ) and the volume of these wells (𝑉𝑉𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤 ).  Using the equation below, the amount of 
solvent on-chip was calculated to be 6.5 µl. 
 𝑆𝑆𝑆𝑆𝑤𝑤𝑆𝑆𝑤𝑤𝑆𝑆𝑡𝑡𝑆𝑆𝑆𝑆−𝑐𝑐ℎ𝑖𝑖𝑖𝑖 = 𝑁𝑁𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤 𝑤𝑤 ∙ 𝑉𝑉𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤        (3.1)  
The amount of PDMS in contact with the fluid is the volume under the impermeable 
layer (𝑉𝑉𝑃𝑃𝐷𝐷𝑀𝑀𝑆𝑆 ) minus the volume of the solvent (𝑉𝑉𝑤𝑤𝑆𝑆𝑤𝑤𝑆𝑆 ).  The Amount of PDMS on-chip 
was calculated to be 68 µl. 
 𝑃𝑃𝐷𝐷𝑀𝑀𝑆𝑆𝑆𝑆𝑆𝑆−𝑐𝑐ℎ𝑖𝑖𝑖𝑖 = 𝑉𝑉𝑃𝑃𝐷𝐷𝑀𝑀𝑆𝑆 − 𝑉𝑉𝑤𝑤𝑆𝑆𝑤𝑤𝑆𝑆        (3.2) 
The amount of solvent absorbed is the volume of PDMS available for absorption (𝑉𝑉𝑃𝑃𝐷𝐷𝑀𝑀𝑆𝑆 ) 
times the absorption of PDMS (𝐴𝐴𝐴𝐴𝑤𝑤𝑃𝑃𝐷𝐷𝑀𝑀𝑆𝑆 ) for the appropriate solvent.  Amount of water 
available to absorb in PDMS was calculated to be 66 nl. 
 𝑆𝑆𝑆𝑆𝑤𝑤𝑆𝑆𝑤𝑤𝑆𝑆𝑡𝑡𝐴𝐴𝐴𝐴𝑤𝑤𝑆𝑆𝐴𝐴𝐴𝐴 = 𝑉𝑉𝑃𝑃𝐷𝐷𝑀𝑀𝑆𝑆 ∙ 𝐴𝐴𝐴𝐴𝑤𝑤𝑃𝑃𝐷𝐷𝑀𝑀𝑆𝑆        (3.3) 
The fraction absorbed is the volume of solvent absorbed into PDMS (𝑉𝑉𝑎𝑎𝐴𝐴𝑤𝑤 ) divided by the 
volume of the solvent on-chip (𝑉𝑉𝑤𝑤𝑆𝑆𝑤𝑤𝑆𝑆 ).  The fraction of water absorbed was calculated to 
be 0.75% 
 𝐹𝐹𝐴𝐴𝑎𝑎𝑐𝑐𝑡𝑡𝑖𝑖𝑆𝑆𝑆𝑆𝐴𝐴𝐴𝐴𝑤𝑤𝑆𝑆𝐴𝐴𝐴𝐴𝑤𝑤𝐴𝐴 = 𝑉𝑉𝑎𝑎𝐴𝐴𝑤𝑤𝑉𝑉𝑤𝑤𝑆𝑆𝑤𝑤𝑆𝑆         (3.4) 
Because PDMS will absorb 20 times more material from organic solvents than 
water, shown in Figure 3.5, experiments with organic solvents cannot be carried out over 
 32 
 
a several day period.  Using equations 3.1 to 3.4, the maximum amount of solvent 
absorption was calculated to be greater than the amount of solvent on-chip (with organic 
solvents). 
Due to PDMS’ propensity for absorbing organic solvents into PDMS, long term 
experiments using organic solvents can’t be carried out on-chip (e.g. temperature control 
and evaporation).  As a result, we are pursuing alternative approaches to crystallizing 
these materials on-chip.   
3.4 Concluding Remarks 
This chapter demonstrates a successful chip for the crystallization of APIs on-chip 
using FID, temperature control and evaporation.  Additionally, methods to analyze the 
crystals on-chip using birefringence and Raman spectroscopy was developed and tested.  
The current challenge with our chip is its absorption of organic solvents.  As a result, the 
current chip needs to be modified such that organic media can be used on-chip. 
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3.5 Figures 
 
 
Figure 3.1 Solubility of Acetaminophen in water.  Comparison of data obtained in this 
study and data obtained Braatz et al. [30]. 
 
 
 
Figure 3.2 Nucleation of Acetaminophen on-chip via evaporation. 
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Figure 3.3 Birefringence of Acetaminophen on-chip.  The above image demonstrates 
birefringence’s ability to identify crystalline material on-chip. 
 
 
 
Figure 3.4 Raman spectrum of Acetaminophen crystals on-chip.  Light red: the spectrum 
of Acetaminophen crystals on-chip and dark red: acetaminophen crystals off-chip. 
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Figure 3.5 Absorbance of common solvents used for crystallization experiments of CDs. 
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Chapter 4: Overcoming On-chip Solvent Absorption 
4.1 Introduction 
Microfluidic technology has grown by leaps and bounds over the last decade.  
Much of the success of microfluidics can be accredited to the material 
polydimethylsiloxane (PDMS).  PDMS’ well understood fabrication procedures and 
elastomeric properties have made it the primary material used in microfluidic devices 
[31-34].  As a result, PDMS microfluidic devices can be seen in biological applications, 
concentration studies, crystallization screening, nucleation studies, PCR analysis, and 
DNA separation to name a few [35-38]. 
While PMDS enables researchers to develop many needed devices and 
applications, use of PDMS is mostly limited to aqueous media [39] due to its inherent 
tendency to absorb certain solvents [40].  Hard materials such as glass and silicon have 
been explored as an alternative for PDMS and other solvent-absorbing polymers [39].  
These hard materials have been used in microelectromechanical systems and microfluidic 
applications; however, these materials lack the properties and valve control needed for 
high levels of fluid manipulation and control [34, 41].   
Solvent-resistant materials are particularly important for crystal screening of CDs 
in microfluidic platforms due to the wide variety of solvents typically used in these 
screens.  Typical solvents for crystallization include isopropyl acetate, ethanol, methanol, 
isopropanol, heptane, acetonitrile, 1-octanol, toluene and 2-butanone, all of get absorbed 
to different extents in PDMS [9, 40].  As a result, a platform for crystallization that is 
compatible with these solvents needs to be developed. 
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4.2 Literature Survey 
Many approaches have been explored in an attempt to overcome solvent 
absorption.  The attempts can be classified in three categories (1) material coatings on 
PDMS devices to create a physical barrier to absorption, (2) alternative materials which 
are both elastomeric and solvent-resistant to replace PDMS, and (3) material reduction 
strategies.  Of these strategies, the most successful are the coating and material reduction 
strategies. 
In regards to material coatings on PDMS, Cytop, a fluoropolymer from Asahi 
glass, has shown the most promise.  Kanai et al. [42] reported the passivation of PDMS 
microfluidic channels with a 0.2-5µm thick coating of Cytop.  Cytop channel coatings 
create a barrier to absorption due to their hydrophobicity.  Cytop can be applied on 
PDMS using several techniques including spin coating, dipping, flowing, and hot 
pressing.  Theses coatings increase the overall young’s modulus of the material, 
therefore, increasing the resistance to valve actuation.  However, valve actuation has been 
demonstrated with increased pressure in Cytop-coated devices.  Cytop was found to 
reduce but not eliminate both the swelling and the rate of absorption from organic 
solvents. 
Other coatings, including Viton, Teflon AF, and metals, have shown promise 
limiting solvent absorption.  Viton, a liquid-castable FKM fluorelastomer, is a coating 
with good chemical resistance which has shown moderate success eliminating solvent 
absorption [39].  Viton (coated via spin coating on PDMS) reduced absorption into 
PDMS where uniform coatings were applied; however, Dam et al. struggled creating a 
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uniform barrier and thus, an effective barrier [39].  Teflon AF, Teflon in a perfluorinated 
solvent, was applied via spin-coating [39].  Teflon AF was found to have extremely high 
solvent resistance; however, Dam et al. found that the high temperatures required for 
annealing cracked the material preventing a uniform coating [39].  Other more common 
and hard materials, such as metals, have been used in an attempt to eliminate absorption; 
however, valve actuation tends to crack the material causing it to fail [39]. 
Beyond material coatings, researchers have evaluated alternative materials for 
PDMS.  The challenge becomes finding a material with the elastomeric properties needed 
for valve actuation, solvent resistance and well understood fabrication techniques.  Natali 
et al. has developed a multilayer thiolene (NOA61) microfluidic chip fabrication 
technique enabling the manipulation of solvents on-chip.  However, valve actuation 
wasn’t incorporated in the thiolene chip [43].  Another material of note is isobornyl 
acrylate.  This material can be easily croslinked with UV light in the presence of 
crosslinker and photoinitiator.  Khoury et al. have developed a simple fabrication 
technique; however, the cured polymer is too hard for valve actuation [44].  The major 
advantage of PDMS over alternative materials is its elastomeric property.  While there 
are many options, the challenge in developing a replacement for PDMS becomes finding 
an elastomeric material with well understood and high density fabrication techniques. 
Researchers have looked into alternative approaches to minimize absorbent 
material.  Mathies et al. has developed a material reduction strategy to minimize 
absorption to the point that organic solvents can be used, as shown in Figure 4.1 [20].  
This approach employs glass fluid and control layers with a thin flexible film between the 
two layers.  The flexible film between the glass layers is made of PDMS, which enables 
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valve actuation.  Using this approach, the thickness of the PDMS membrane can be 
reduced from more than 2 mm to less than 100 microns.  This approach has been 
demonstrated to be compatible with organic solvents due to the reduced amount of 
PDMS required.  Manalis et al. have taken Mathies’ approach and replaced the PDMS 
membrane with a solvent resistant Teflon FEP (a fluorinated ethylene propylene from 
DuPont) film [45].  Incorporating this Teflon film eliminates all unwanted absorption.  
Teflon FEP films with glass chips have been demonstrated to work with organic solvents 
in a leak-free fashion. 
4.3 Coatings to Eliminate Solvent Absorption 
Coatings such as Cytop have been employed in an attempt to reduce solvent 
absorption.  Cytop was spun onto the PDMS device, dried, annealed and tested for 
resistance to solvent absorption.  Cytop 809-A was mixed 1:10 with Fluorinert FC-75 and 
spun onto PDMS at 500 RPM to produce at roughly 5µm coating.  Following spin 
coating, the chip was baked at 75°C for 30 minutes and annealed at 115°C for 30 
minutes.  Cytop appeared to form a uniform coating. The coating reduced the elasticity of 
the PDMS mold; however, the valves could still be actuated with increased pressure.  
Unlike previous studies, our studies avoided crack formation within the Cytop material as 
the result of valve actuation.  This is believed to be due to the incorporation of actuate-to-
open valves rather than actuate-to-close valves.  The actuate-to-open valves flex the 
material less, which prevented the material from cracking.  While the material coated the 
device well and formed a uniform coating without cracks, we experienced solvent loss 
with the coated chip to a similar extent on an uncoated chip with water solutions.  These 
results show that Cytop does not form a sufficient physical barrier for solvents.   
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4.4 Alternative Materials and Approaches to Eliminate Solvent Absorption 
A variety of thiolene materials (NOA 60, 61, 63, 65, 68, 70, 75, 76, 81) were also 
coated on our PDMS chip to reduce absorption.  These materials have a wide range of 
properties regarding adhesion and elasticity.  Each thiolene material was spin coated  
(1) directly onto the PDMS mold and (2) directly onto the silicon master.  When spinning 
onto a silicon master, the materials (a) failed to adhere to the PDMS master poured on top 
of it, (b) permanently adhered to the silicon master, or (c) prevented valve actuation due 
to increased stiffness of the film.  When spinning thiolene directly onto PDMS, the 
materials would either (a) not uniformly coat the device or (b) prevent valve actuation 
due to increased stiffness of the film.  Thiolene was found to make a poor coating 
material due to adhesion incompatibilities and insufficient elasticity. 
We also attempted to replace the PDMS material altogether with thiolene (NOA 
76).  NOA 76 was chosen due to its low Young’s modulus (6600 kPa), which is 7.5 times 
that of PMDS (870 kPa).  Silicon masters were made from masks which selectively 
blocked UV light to develop the desired structure on a silicon wafer.  The pattern on the 
silicon wafer was used to mold a PDMS master, which, in turn, was used to mold the 
fluid and control layers out of thiolene.  The thiolene material was spun onto the PMDS 
master and exposed to UV light to crosslink the material.  Once crosslinked, the layers 
were combined and further crosslinked under UV light for permanent bonding.  While the 
fabrication procedure was simple, the higher Young’s modulus of thiolene prevented the 
material from flexing under a vacuum pump with a pressure as high as 0.2 bar.  Higher 
pressure gradients than are available in an atmospheric environment are necessary to 
actuate these valves.   
 41 
 
Due to the challenges associated with incorporating alternative materials and 
coatings to PDMS devices, glass-based microfluidic devices based on technology 
Mathies et al. developed were explored.  The design used in the PDMS approach 
discussed in chapter 2 was transferred to glass slides.  Our control and fluid design 
patterns have been transferred to glass slides.  These glass slides are sandwiched together 
with a thin PDMS or Teflon FEP film separating the glass slides.  See Figure 4.1 for 
explanation regarding the alignment of the layers.   
The procedure for glass fabrication is as follows: Glass slides are coated with 30 
microns of chrome with 150 microns of Gold.  The second chrome and gold coatings 
improve adhesion and eliminate pin-hole defects observed with only one coating.  The 
coated slide is selectively patterned with SPR220 using computer-generated masks.  The 
exposed Cr/ Au is etched, exposing the glass.  The channels and wells are subsequently 
etched with HF where the glass is exposed.  After the glass slide is etched, the remaining 
photoresist, chrome and gold are removed, exposing the glass slide.  The etched glass 
slides are sandwiched together with a 20 micron PDMS film between.  
The combined devices worked moderately well.  Valve actuation was successful.  
However, the chip leaks around the valves and chambers, as shown in Figure 4.2.  The 
chamber and valve spacing need optimization to improve fluid containment.  
4.5 Concluding Remarks 
A major problem with PDMS microfluidic chips is its high rate of solvent 
absorption.  Many materials, coatings, and alternative approaches have been explored in 
an attempt to discover a chip that can meter, isolate and control fluid flow on-chip while 
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maintaining solvent compatibility. The alternative approach based on a glass chip 
developed by Mathies shows promise to eliminate solvent absorption.   
With the proper modifications, this approach holds promise for development of a 
chip that will isolate and control fluid movement on-chip while overcoming our 
challenges of solvent absorption.  
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4.6 Figures 
 
Figure 4.1 Microfluidic valve fabrication in glass as reported by Mathies et al. [20]. 
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Figure 4.2 Depicted is a glass based microfluidic device built for crystallization 
screening.  The filled chambers are in the fluid layer and the unfilled chambers are in the 
control layer.  This figure demonstrates successful etching, and fluid filling.  Leaking can 
be seen around the fluid lines. 
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Chapter 5: Conclusion 
5.1 Concluding Remarks 
This thesis reported the development, fabrication and application of a microfluidic 
chip for the screening of candidate drugs (CD) in regards to conditions favorable for 
crystallization.  The platform screens for available solid forms of a CD, which is the first 
step in identifying the physiological properties of CDs.  In turn, this provides insight 
regarding the propensity of the CD for attrition or long R&D processes.  Three main 
methods are used to increase supersaturation, and thereby to induce crystal nucleation 
and growth: (1) free interface diffusion which increases the likelihood of nucleation 
compared to microbatch the most common macroscale technique, (2) temperature control 
by an external source and (3) evaporation, incorporating an additional layer with 
evaporation channels, with evaporation times between 10 and 50 hours.  The microfluidic 
platform is comprised of 96 wells that each consume 50 nl of CD solution, so typically 
less than 5 micrograms of a CD per well.   
The functionality of this platform is demonstrated with acetaminophen using the 
three methods discussed above.  Using free interface diffusion (with antisolvents), 
temperature control and evaporation, conditions favorable for nucleation were identified.  
The free interface diffusion technique was compared to a conventional microbatch oil 
submersion method.  In this comparison, more hits were observed on-chip than off-chip.  
Additionally, the chip was modified for Raman spectroscopy to be obtained from crystals 
on-chip.  This allows for the identification of crystalline solids and polymorphs.   
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5.2 Future Work 
While the platform’s capabilities have demonstrated screening potential with 
aqueous media, the microfluidic platform is incompatible with most organic solvents for 
long term experiments (>8 hrs) due to solvent absorption.  As a result, alternative 
materials and coatings have been explored.  While using alternative materials and 
coatings, challenges with sealing between layers, swelling, cracking and limited valve 
actuation prevented their successful incorporation.  Similar challenges are reported in 
literature.  Mathies et al. has developed a valve design that limited the PDMS material 
via incorporating channels in glass slides with a thin PDMS or Teflon membrane.  
Incorporating the current PDMS design discussed in Chapter 2 with Mathies’ technique 
shows significant promise for limiting solvent absorption.  Thus so far, a significant 
amount of leaks on-chip due to poor sealing and improper spacing of valves, lines, 
chambers, etc have limited immediate incorporation.  To overcome this challenge, 
additional experiments are needed to better understand the design rules such as proper 
spacing between valves and valve widths.  By first doing experiments to understand the 
design rules associated with this approach, we will gain a better understanding of the 
optimal dimensions that will allow us to develop a glass based microfluidic platform 
capable of screening for crystallization conditions of pharmaceuticals.  This device will 
use the same approach seen in the PMDS based microfluidic chip with the advantage of 
improved compatibility with organic solvents.   
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